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Abstract Adjuvant chemotherapy is often needed to
achieve adequate breast cancer control. The increasing
popularity of immediate breast reconstruction (IBR) raises
concerns that this procedure may delay the time to adjuvant
chemotherapy (TTC), which may negatively impact
oncological outcome. The current systematic review aims
to investigate this effect. During October 2014, a system-
atic search for clinical studies was performed in six data-
bases with keywords related to breast reconstruction and
chemotherapy. Eligible studies met the following inclusion
criteria: (1) research population consisted of women
receiving therapeutic mastectomy, (2) comparison of IBR
with mastectomy only groups, (3) TTC was clearly pre-
sented and mentioned as outcome measure, and (4) original
studies only (e.g., cohort study, randomized controlled
trial, case–control). Fourteen studies were included, rep-
resenting 5270 patients who had received adjuvant
chemotherapy, of whom 1942 had undergone IBR and
3328 mastectomy only. One study found a significantly
shorter mean TTC of 12.6 days after IBR, four studies
found a significant delay after IBR averaging
6.6–16.8 days, seven studies found no significant differ-
ence in TTC between IBR and mastectomy only, and two
studies did not perform statistical analyses for comparison.
In studies that measured TTC from surgery, mean TTC
varied from 29 to 61 days for IBR and from 21 to 60 days
for mastectomy only. This systematic review of the current
literature showed that IBR does not necessarily delay the
start of adjuvant chemotherapy to a clinically relevant
extent, suggesting that in general IBR is a valid option for
non-metastatic breast cancer patients.
Keywords Immediate breast reconstruction 
Chemotherapy  Mastectomy  Breast cancer  Systematic
review
Introduction
One out of every eight women will be diagnosed with
breast cancer in her lifetime, making it the most common
cancer in women [1]. Over the last decades the survival
rate has increased slowly, which is currently estimated to
be 85 % in developed countries [2]. However, with an
estimated annual number of breast cancer deaths of
537,000 worldwide, breast cancer still is the most impor-
tant cause of death by cancer among women [3].
Despite advances in different treatment modalities,
about 45 % of all breast cancer patients still undergoes a
mastectomy for adequate local control [4, 5]. The resulting
loss of a breast may have a negative effect on body image,
sexuality, and sense of femininity [6]. Breast reconstruc-
tion aims to diminish the negative psychological impact of
mastectomy and to improve patients’ quality of life. Cur-
rently, approximately 20–40 % of women who undergo a
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mastectomy receive breast reconstruction [1]. Breast
reconstruction can either be performed immediately fol-
lowing mastectomy during the same operation or as a
delayed procedure after completion of the entire oncologic
treatment. Immediate breast reconstruction (IBR) has sev-
eral reported advantages, such as favorable esthetic out-
comes and less psychological burden, avoiding additional
operations, hospitalizations, and costs [4].
A disadvantage of IBR is the increased risk of postop-
erative complications, which causes concerns regarding
oncological safety [7]. Almost 39 % of medical oncologists
and 23 % of surgical oncologists feel that breast recon-
struction adversely interferes with adjuvant oncological
therapy [8]. One concern is that IBR increases the time to
adjuvant chemotherapy (TTC), which may have a negative
impact on recurrence and survival rates. To put a possible
delay in the administration of adjuvant chemotherapy into
perspective, it needs to be established from which point on
this delay negatively affects oncological safety and, hence,
becomes clinically relevant.
Various studies aimed at identifying the cut-off point
after which increased TTC has a significant negative
impact on survival. In relation to relapse-free survival,
disease-free survival or overall survival in non-metastatic
breast cancer patients, no such cut-off point has been
identified, given chemotherapy was started within
3 months after surgery [9–13]. One study, however, iden-
tified a subgroup of premenopausal patients with ER-neg-
ative node-positive tumors who showed impaired disease-
free survival if chemotherapy was started 21–86 days
versus within 20 days after surgery [10]. Furthermore, in
patients with stage I or II breast cancer relapse-free sur-
vival and overall survival were found to significantly
decrease if chemotherapy was postponed more than
3 months after surgery [12].
The purpose of this study was to perform a systematic
review of the current literature to investigate whether TTC
is affected by IBR compared with mastectomy only.
Methods
Within the databases Embase, Medline (PubMed), Web of
Science, Scopus, the Cochrane Central, and Google Scho-
lar studies on the effect of IBR on TTC in breast cancer
patients were searched on 6 October 2014. Keywords
related to breast reconstruction, chemotherapy, and a
clinical study design were used. The exact search string is
shown in the appendix. No limitations were placed on
study design, language, or otherwise. References were
checked for duplicity and deleted accordingly.
Two reviewers (JXH and CAEK) independently asses-
sed the title and abstract of all references with the
following inclusion criteria: (1) the research population
consists of women undergoing a mastectomy for breast
cancer, (2) the study compares a cohort receiving IBR with
one receiving mastectomy only, (3) timing of adjuvant
chemotherapy is mentioned as outcome measure and is
appropriately quantified, and (4) the publication concerns
an original study (i.e., cohort study, randomized controlled
trial, case–control, case study). Conference abstracts and
reviews were excluded. In case of disagreement between
two reviewers, a third reviewer (EB) made the final
decision.
Subsequently, the full text of the selected studies was
reviewed for final inclusion. If deemed necessary, authors
were contacted with a request to provide additional infor-
mation or clarification. Next, the reference lists of these
finally included studies were searched for references to
other relevant studies, which had not been included in the
original search. The selection of these references was
performed using the same criteria as mentioned above.
Study quality was assessed through an estimation of bias
due to various causes [14]. Data were extracted using a
predefined extraction form. Information was obtained on
study design, patient characteristics (including comorbidi-
ties), outcome measures regarding TTC, and variables
regarding other aspects of adjuvant chemotherapy.
Statistical analysis
If only median values were reported, authors were con-
tacted with a request to provide mean values and standard
deviations, to enable us to calculate 95 % confidence
intervals of the mean differences.
Clinical and statistical heterogeneity were assessed and,
if deemed sufficiently low, a meta-analysis was performed
using pooled data. Statistical heterogeneity was determined
using the I2 index. An I2 value smaller than 25 % was
considered to indicate low heterogeneity, a value of
25–50 % moderate heterogeneity, and a value above 50 %
high heterogeneity [15]. If I2 was low or moderate a fixed
effects model was used, whereas we used a random effects
model if the I2 index indicated high heterogeneity. Overall
effect was calculated as a Z-statistic, with 95 % confidence
intervals, and regarding a p value less than 0.05 as sig-
nificant. Review Manager 5.3 (Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2014) was
used for statistical analysis.
Results
The literature search yielded 1978 unique publications and
after applying the selection criteria 25 publications were
read in full text, of which 14 were finally included (Fig. 1)
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[7, 16–28]. The initial consensus between the reviewers
after screening of title and abstract was 99.4 %. Screening
of the reference lists of the included papers did not result in
the inclusion of additional studies. Four studies were
included only after essential information was acquired
through correspondence with the authors [19, 20, 25, 27].
Extra information was received for three other studies as
well [7, 21, 23].
Study characteristics and quality
The study characteristics are shown in Table 1. As
expected, no randomized controlled trials were found on
IBR and adjuvant chemotherapy. All included studies were
retrospective cohort studies, of which one used matching to
define a control cohort. It should be noted that Alderman
et al. [16] and Vandergrift et al. [27] partly cover the same
patient population for the entire year of 2003.
The results of the quality assessment are shown in
Table 2. Few studies reported information about follow-up.
In most studies patients were included if they received
chemotherapy and therefore patients who started
chemotherapy late may have been missed if follow-up was
insufficient to identify them.
Table 3 shows the patient characteristics of the studies
included in the current review. Few studies reported data
on patient age, comorbidity, and risk factors for postoper-
ative complications and even fewer studies reported these
characteristics specifically for patients who had received
chemotherapy. Therefore, it was not possible to provide an
overview of these variables.
Study heterogeneity
The patient populations were compared regarding the
inclusion criteria used and the available patient character-
istics in order to determine the clinical heterogeneity. Due
to lack of pertinent information, the legitimacy to do a
meta-analysis was doubted. Moreover, an I2 of 98 % was
observed, after pooling the studies that used the same
definition for time to chemotherapy and reported mean
values and standard deviations [7, 17, 20, 22, 23], indi-
cating a high statistical heterogeneity. We found no obvi-
ous explanation for this high statistical heterogeneity.
Consequently, no meta-analysis was performed.
Time to chemotherapy
The included studies reported TTC in different formats
(Table 4 and Fig. 2). Originally, seven studies reported
TTC as a mean value and seven as a median value. The
authors of one of the studies that reported medians pro-
vided us with means and standard deviations on request [7].
If the required information was available, the 95 % confi-
dence interval was computed for the mean differences.
Alderman et al. [16] only reported values for two separate
age groups instead of the total patient group.
In the twelve studies that measured TTC from surgery, it
varied between 29 and 61 days in the IBR groups and
between 21 and 60 days in the patient groups that received
mastectomy only. Differences in TTC between the IBR
groups and the mastectomy only groups varied widely from
a 12.6 days reduction in average TTC after IBR to a delay
of 11.9 days in average TTC after IBR [7, 16–20, 22–26,
28]. One study found a significantly shorter TTC after IBR
[17], three studies found a statistically significant delay
following IBR [7, 22, 24], six studies found no statistically
significant difference in TTC between IBR and
Fig. 1 Flowchart of the study selection procedure
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mastectomy only [18–20, 23, 25, 28], and two studies did
not perform a statistical test for the comparison [16, 26].
Two studies used a different definition for TTC. Kahn
et al. [21] measured TTC starting from the multidisci-
plinary decision to administer adjuvant treatment and
reported a TTC of 31 days for IBR and of 29 days for
mastectomy only, resulting in a statistically non-significant
difference of 2 days. TTC was measured from pathological
diagnosis by Vandergrift et al. [27], reporting 96.6 days for
IBR and 79.8 days for mastectomy only, with a difference
of 16.8 days. It was clarified via correspondence that this
multidisciplinary decision was made after surgery (L.
Romics Jr., personal communication), whereas the patho-
logical diagnosis was made before the operation. These
differences in definitions should be kept in mind when
evaluating and comparing TTC published in the different
studies.
Comparing the upper ranges gives insight of the TTC for
the extremes in each cohort. Those maximum values were
similar or lower for the IBR groups than for the mastec-
tomy only groups. Furthermore, in 4 out of 6 studies pre-
senting ranges, all patients started chemotherapy within
13 weeks after IBR.
Two studies performed a multivariate analysis correct-
ing for various sociodemographic, clinical, therapeutic, and
diagnostic factors. Alderman et al. [16] found a
significantly shorter TTC for patients younger than
40 years after mastectomy only; at older ages no significant
differences were found between IBR and mastectomy only.
Vandergrift et al. [27] found a significantly shorter TTC
following mastectomy only, even after multivariate
correction.
Other chemotherapy-related outcomes
Six studies reported the number of patients that had
received chemotherapy after a certain point in time in the
comparison of IBR with mastectomy only. Different cut-
off points were chosen: two studies chose 8 weeks, three
studies chose 12 weeks, and one study reported the number
of patients per 10 days. No statistically significant differ-
ences for this comparison were found for these cut-off
points [7, 16, 18, 20, 22, 26]. In patients with IBR, the few
delays beyond 12 weeks after surgery were not related to
the type of surgery, but due to social reasons and delayed
diagnostic test results [7, 20].
Out of eight included studies which reported the
occurrence of complications, two studies found signifi-
cantly more complications in the IBR group [22, 23] and
six studies did not find a significant difference (in one study
after adjusting for confounders) between IBR and mas-
tectomy only [7, 18–20, 24, 25]. Three studies evaluated
Table 1 Characteristics of the included studies on IBR and adjuvant chemotherapy
Year of
publication
Research
period
Country Typea Center Patient recruitment (and extra data source)
Alderman [16] 2010 1997–2003 USA RCS Multi Prospectively maintained database
Allweis [17] 2002 1996–2000 USA RCS Single Hospital tumor registry (and medical records)
Chang [18] 2013 2003–2009 Australia RCS Single Prospectively maintained database
Eriksenb [19] 2011 1990–2004 Sweden RMCS Single Prospectively maintained database
Hamahatab [20] 2013 2006–2011 Japan RCS Single Medical records
Kahnb [21] 2013 2008–2011 UK RCS Single Prospectively maintained database (and medical records)
Lee [22] 2011 2008–2010 Korea RCS Single Institutional electronic patient database and medical records
Mortensonb [23] 2004 1995–2002 USA RCS Single Medical records
Newman [24] 1999 1990–1993 USA RCS Single Prospectively maintained database
Reyb [25] 2005 1999–2002 Italy RCS Single ?
Taylor [26] 2004 1999–2002 UK RCS Single Regional tumor registry
Vandergriftb [27] 2013 2003–2009 USA RCS Multi Prospectively maintained database (and medical records)
Wilson [28] 2004 1995–2000 UK RCS Single Database (and the case notes crosschecked with the
pharmacy records)
Zhongb [7] 2012 2007–2010 Canada RCS Single Prospectively maintained database
IBR immediate breast reconstruction
a RCS retrospective cohort study; RMCS retrospective matched cohort study
b Additional information about this paper was required through correspondence with the authors
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the effect of these complications on TTC. One study
showed a significantly longer TTC for patients with com-
plications compared to patients without complications [22].
However, for patients with complications none of these
studies showed a statistically significant difference in TTC
between the IBR and mastectomy only groups [20, 22, 23].
Four studies that looked at TTC after various types of
breast reconstruction could not find statistically significant
differences [17, 20, 22, 28]. There were also no significant
differences reported between IBR and mastectomy only in
delay relative to planned initiation, dose reduction, delay
during cycles or incomplete regimens [18, 19, 23, 26].
Besides TTC, omission of chemotherapy may influence
oncological outcome. Only one study investigated this.
Patients were included if they required adjuvant
chemotherapy according to treatment guidelines. No sta-
tistically significant difference in omission of chemother-
apy was found between the IBR and mastectomy group
[16].
Discussion
This systematic review shows that IBR does not necessarily
delay the start of adjuvant chemotherapy to a clinically
relevant extent [9–13]. Differences in TTC between the
IBR groups and the mastectomy only groups varied widely,
ranging from a 12.6-day shorter TTC for IBR to a 16.6-day
shorter TTC for mastectomy only. Out of 14 studies 10
studies reported a difference in TTC of less than a week
Table 2 Quality assessment of the included studies on IBR and adjuvant chemotherapy
Study Bias due to a non-
representative or ill-
defined sample of
patients
Bias due to insufficiently long, or
incomplete follow-up, or
differences in follow-up between
treatment group
Bias due to ill-
defined or
inadequately
measured
outcomes
Bias due to inadequate
adjustment for all
important prognostic
factors
Unclear or
inconsistent
reported
outcome
measure
Alderman [16] UL UL UL Lf No
Allweis [17] UL ? UL Lg Yesi
Chang [18] UL ? UL Lg No
Eriksena [19] UL Lc UL Lh No
Hamahataa [20] UL ? UL Lg Yesi
Kahna [21] UL ? Ld Lh No
Lee [22] UL ? UL Lg No
Mortensona [23] UL ? UL Lh Yesi
Newman [24] UL UL UL Lh No
Reya [25] ?b UL UL Lg Yesj
Taylor [26] UL ? UL Lh No
Vandergrifta [27] UL UL ULe Lf No
Wilson [28] ?b ? UL Lh Yesi
Zhonga [7] UL ? UL Lg No
UL unlikely; ? unclear; L likely; IBR immediate breast reconstruction; CTx adjuvant chemotherapy; TTC Time to adjuvant chemotherapy
a Additional information about this paper was required through correspondence with the authors
b Patient selection unclear
c Lost to follow-up for TTC: 15 and 24 % for IBR and mastectomy, respectively
d TTC measured from multidisciplinary decision to administer adjuvant treatments instead of final operation, allowing for other factors than type
of operation to affect TTC, which is inconsistent with the study purpose
e Alternative definition for TTC, but consistent with the study purpose
f Corrected for some but not all. For example type of reconstruction and smoking behavior were omitted
g Some data on possible confounders reported, but adjusted for none
h Did not report data on possible confounders for patients receiving CTx
i Different values for the same outcome measure reported
j Type of point estimator not stated (clarified by e-mail)
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between these two groups. Two important reasons for delay
of chemotherapy may equally apply to any surgery: diffi-
culties in planning the surgery and surgical complications.
First, difficulties in planning a multidisciplinary surgery
such as IBR, probably delays start of chemotherapy. This is
an explanation for the average delay of 16.6 days found by
Vandergrift et al. as they measured the interval from
pathological diagnosis to chemotherapy [27]. In this
approach factors other than the surgical procedure itself
will affect the measurement. For example, planning IBR
surgery most likely takes more time than planning a mas-
tectomy only, due to additional outpatient visits of different
specialists before surgery, more operation time, and extra
surgeons are necessary for performing IBR compared to
mastectomy. All other studies measured TTC as of the date
of surgery or multidisciplinary decision and were therefore
incapable of identifying possible delays due to logistical
difficulties in planning IBR. Besides planning of the sur-
gery, other factors may influence TTC, such as different
local protocols and the person deciding on the actual start
of chemotherapy. Delays due to difficulties planning sur-
gery may be reduced in case adequate logistical measures
are taken. For example, scheduling the availability of a
combined oncologic and plastic surgery operation room for
IBR at regular intervals. In case of relatively long absolute
TTC, local treatment protocols should be reassessed. With
the growing trend towards multidisciplinary approach in
health care generally, efficient planning and adequate
protocols are key to avoid unnecessary delays. Such diffi-
culties should not reduce the usage of multidisciplinary
therapies such as IBR.
Second, the studies included in this review suggest that
complications after IBR do not result in longer TTC
compared to complications after mastectomy only. Com-
plications in general are considered to delay chemotherapy
and this was confirmed in one study recording a longer
TTC for patients with complications compared to patients
without complications [22]. There was no conclusive evi-
dence that IBR gave rise to more complications than
mastectomy only. Six studies found no difference in
complication rate [7, 18–20, 24, 25]. One of them reported
more complications with IBR in unadjusted data, but not
after correction for confounders (previous surgery, previ-
ous radiotherapy, bilateral surgery) [7]. Two studies found
more complications in the IBR group, but did not collect
data on these confounders or did not correct for them while
there were clear differences between the treatment groups
[22, 23]. One study showed bilateral breast surgery results
in more complications, although not proportionally more
than two unilateral breast surgeries. Since the feasibility of
IBR might increase the demand on contralateral prophy-
lactic mastectomy by women with unilateral breast cancer,
as a consequence the absolute number of complications
may increase compared to unilateral breast surgery [29].
Fig. 2 Differences between IBR and mastectomy only in time to
chemotherapy in days. IBR immediate breast reconstruction; M mas-
tectomy only. aAdditional information about this paper was required
through correspondence with the authors. bTime to chemotherapy
measured from pathological diagnosis. cTime to chemotherapy
measured from multidisciplinary decision
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None of these studies showed a statistically significant
difference in TTC between the IBR and mastectomy only
groups for patients with complications [20, 22, 23].
The clinical relevance of a delay must be assessed in
relation to absolute findings of TTC. No study reported an
average interval from surgery to start of chemotherapy
longer than the clinically relevant limit of 12 weeks after
surgery [12]. As mentioned before, variation in com-
mencement date of chemotherapy within 3 months maxi-
mum after surgery does not seem to have a significant
effect on survival rates [9–13]. Consequently, no major
impact on oncological safety is to be expected due to the
reported average delays in TTC.
There are a few limitations to this review. Our quality
assessment showed that most studies were potentially
subject to bias. However, this was not to such an extent that
a specific study had to be excluded from the review. It
proved difficult to specifically examine the effect of IBR on
TTC, because the majority of the studies reported general
patient characteristics only without possible confounders or
correcting for them. Some studies showed considerable
differences in patient characteristics between the IBR and
mastectomy only group. Furthermore, it is plausible that
different types of breast reconstruction may have different
effects on TTC, but only four studies investigated this
issue. These studies did not find statistically significant
differences, which may be due to small patient numbers
[17, 20, 22, 28]. In two studies that corrected for various
possible confounders, a statistically significant delay in
TTC associated with IBR was found [16, 27]. In one study
this finding was restricted to patients under 40 years of age
[16]. Many studies used the administration of adjuvant
chemotherapy as an inclusion criterion. It is possible that
certain patients were missed out, in which case they
received chemotherapy at another institution or at a later
point in time than the follow-up period. Unfortunately,
follow-up was not specifically reported in most studies.
One study explicitly recorded that patients whose
chemotherapy started more than 32 weeks after diagnosis
were excluded [27]. As a result there may be bias, because
patients with chemotherapy delayed beyond that period are
taken out of the equation.
Since most studies report only on TTC as an average,
they do not provide a basis for identifying outliers.
Increased oncological risk may impact the few patients
subject to the longest delays. Regardless, there was no
significant difference in the number of patients with a TTC
longer than 8 between IBR and mastectomy only [16, 18].
The same goes for patients with a TTC longer than
12 weeks [7, 20, 22]. The reasons given for the limited
number of delays beyond 12 weeks after surgery were
unrelated to the type of surgery, but due to social reasons
and delayed diagnostic test results. The upper ranges of
TTC were favorable for IBR.
Patients most susceptible for negative effects of delay
may be those with the most aggressive tumors and meta-
static disease. However, it is not really clear what the effect
of delay in TTC is for those patients. Consequently, any
delay due to IBR is of greater concern in this particular
patient population. This systematic review did not include
an analysis of the effect of IBR on TTC for specific sub-
groups potentially at risk [10], because the included studies
did not provide data for such subgroups.
Beside the effect of IBR on TTC, there are concerns
about postoperative morbidity resulting from the combi-
nation of IBR with radiotherapy or chemotherapy. First, a
meta-analysis showed a negative effect on postoperative
morbidity in patients receiving immediate breast recon-
struction in case of adjuvant radiotherapy. However,
delaying breast reconstruction until radiotherapy is finished
did not improve postoperative morbidity. Autologous
reconstruction resulted in less postoperative morbidity than
implant-based reconstructions [30]. Second, IBR seems
safe in patients who received neoadjuvant chemotherapy,
as this did not increase the complication rate [31]. The
marginal delay in delivery of adjuvant chemotherapy could
be an argument to support the growing popularity of
neoadjuvant chemotherapy. Third, one review suggested
that the combination of IBR and adjuvant chemotherapy
does not have a negative effect on surgical complications,
postoperative wound healing, chance of reconstructive
failure, or esthetic outcomes [32]. Finally, the effect of IBR
on the oncological outcome in terms of recurrences is an
issue. However, a meta-analysis comparing local and sys-
temic recurrence rates after IBR and mastectomy only in
locally advanced breast cancer patients did not show sta-
tistically significant differences [33].
Presently available evidence shows that IBR is safe with
regard to the timing of adjuvant chemotherapy. Neverthe-
less, future developments in breast cancer treatment may
require a reassessment. Future studies should identify and
report possible confounders and adjust for them. In addi-
tion, inclusion and analysis of local protocols on the
planning of adjuvant chemotherapy will be helpful to put
the findings into perspective. Most studies included in this
review had risk of bias, which further research should try to
avoid, in order to allow for more reliable conclusions. It
would seem important to further analyze the effect of IBR
on other chemotherapy-related outcomes, such as dose
reduction, delay during cycles, incomplete regimens or
omission, as these also represent aspects of oncological
safety. Finally, a systematic evaluation of the effect of
adjuvant chemotherapy on breast reconstruction in terms of
complication rates, esthetic outcome, and patient
Breast Cancer Res Treat (2015) 153:241–251 249
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satisfaction would be required for more detailed and con-
clusive findings outside the scope of this review.
In conclusion, after critical appraisal of the current lit-
erature, we found that IBR does not necessarily delay
chemotherapy to a clinically relevant extent. With efficient
logistics and adequate treatment protocols the risk of
crossing the described 12-week barrier can be avoided.
This would suggest that in general IBR is a valid option for
non-metastatic breast cancer patients.
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